Article in Leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
6 authors.
Michael E LawlerDepartment of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-8787-6616
Melanie L GoetzDepartment of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-9584-8634
Jennifer S Romer-SeibertDepartment of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
Holly A GamlenDepartment of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
Edwina McGlinnEMBL Australia, Australian Regenerative Medicine Institute, Monash University, Clayton, VIC, Australia.
Sara E MeyerDepartment of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA. sara.meyer@jefferson.edu.ORCID http://orcid.org/0000-0003-2930-748X
Funding
X-Ray Crystallography and Macromolecular CharacterizationP30CA056036 · NCI · THOMAS JEFFERSON UNIVERSITY · PI Claudio Guillermo Giraudo · 1995 to 2026
$94.8M
Integration of epigenetic and non-coding RNA mechanisms in leukemiaR37CA226433 · NCI · THOMAS JEFFERSON UNIVERSITY · PI MEYER, SARA E · 2018 to 2024
$2.5M
Training Grant in Cellular, Biochemical and Molecular SciencesT32GM144302 · NIGMS · THOMAS JEFFERSON UNIVERSITY · PI DIANE E MERRY, PHILIP B WEDEGAERTNER · 2022 to 2026
$2.0M
Training Program in Cancer BiologyT32CA236736 · NCI · THOMAS JEFFERSON UNIVERSITY · PI APLIN, ANDREW ERIC, LANGUINO, LUCIA R. · 2019 to 2023
$1.1M
Interrogation of TLR2 Inflammatory Signaling in AMLF31CA268843 · NCI · THOMAS JEFFERSON UNIVERSITY · PI LAWLER, MICHAEL · 2022 to 2023
$94k
Concern Foundation Conquer Cancer Now AwardNCI NIH HHS F31 CA268843NCI NIH HHS P30 CA056036NCI NIH HHS R37 CA226433NCI NIH HHS T32 CA236736NIGMS NIH HHS T32 GM144302
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
miR-196b-Oct1/2 axis regulates DNMT3A-mutant AML pathogenesis. · full record | OpenQuestion